Established in 2012, CANbridge is a global biopharmaceutical company delivering life-changing therapeutics from a foundation in China. We are dedicated to developing next-generation rare disease treatments to address life-threatening medical conditions with highly unmet medical needs in China and Asia and the rest of the world.
Over the years, CANbridge has built a world-class management and advisory team with the capability to select, acquire, develop, and deliver promising therapeutics to address the severely underserved medical needs of patients globally. The company has also entered into strategic cooperation with GC Pharma, WuXi Biologics, EUSA Pharma, Pierre Fabre, and Apogenix. Additionally, CANbridge has formed collaboration agreements with UMass Medical School for rare disease gene therapy and has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics to develop, manufacture, and commercialize gene therapy candidates for Fabry and Pompe diseases.